

Crossing Over and Under

Rising Star and Falling Angel Candidates

- With pressure from shareholders, LBO activity, and a still difficult macro-backdrop, some companies are at risk of moving to high yield. Conversely, other credits have traversed the recovery with strong balance sheets and improving earnings. This, coupled with management's commitment to higher ratings, positions them for an upgrade to investment grade.
- We present rising star and falling angel candidates and suggest trading strategies for the names. We note that an upgrade / downgrade doesn't always mean spreads trade tighter / wider, as many credits trade in line with their new rating prior to a change.
- Our falling angel candidates operate in sectors experiencing secular weakness or have struggling business models and include Alcoa, AngloGold, Harsco and Transocean.
- Credits with potential to be upgraded to IG have benefited from low natural gas prices, a housing market recovery, and improving business profiles. These include Ashland, Celanese, Continental Resources, Delphi, DR Horton, Sally Beauty and Toll Brothers.

Erin Lyons

+1-212-723-1102
erin.lyons@citi.com


Julie Pearson

+1-212-723-3099
julie.pearson@citi.com

Lili Yang

lili1.yang@citi.com

Figure 1. Potential Falling Angels and Rising Stars



Source: Citi Research

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Crossing Over and Under


The crossover segment of the credit market has enjoyed a strong run over the last couple of years. Triple-B paper has gained relative to the rest of investment grade because of investor preference for high-beta products, and double-B bonds held their own for much of 2012 as declining Treasury yields supported valuations. Unfortunately, that won't be enough going forward. Spread gaps between rating categories have collapsed and Treasury rates are bouncing off the fall lows. In short, credit selection will become more critical.

Further complicating matters, investors have become better at traversing the technicals resulting from index transition, thereby causing the usual out/underperformance to be less reliable. In this article we detail our expectations for crossovers and recommend certain trades based on fundamental views and potential index transition.

One thing we have noticed is that upgrades to investment grade don't always guarantee an outperforming bond. In May 2012, Moody's raised Ford Motor Company's ratings two notches from Ba2 to Baa3, citing the company's strong market position in North America, good liquidity and its disciplined operating and financial policies as reasons for an upgrade. However, upon news of the upgrade, Ford spreads surprisingly widened. We suspect that many added Ford to their IG books ahead of the upgrade, and once the news was out, the bid for paper waned. Perhaps the credit will get some momentum when it holds an IG rating from all agencies.


On the flip side, ArcelorMittal performed better after being downgraded. When S&P first took the company's ratings down to BB+ in August 2012, the market was taken by surprise and spreads widened. When Moody's followed with a downgrade to Ba1 in November, bonds rallied. We think that high yield investors were happy to have a new name to trade, and given its importance in the index, there was a strong bid from index-benchmarked investors (e.g. ETFs). Further, compared to other steel sector options in HY, Mittal spreads look attractive given its market leader position and manageable leverage.

Figure 2. Ford sold-off when upgraded
OAS (bp)



Source: Citi Research, Bloomberg

Figure 3. MTNA rallied on second downgrade
YTW (%)




Source: Citi Research, Bloomberg

Finding the candidates

After the turmoil in ratings in 2008/09, we've seen ratings hold fairly steady over the past few years, and the set of credits poised to change ratings classes is limited. Historically, the balance between IG and HY moves has been skewed towards falling angels, which accounted for 70% of ratings shifts from 2006-2010. This


balance reversed in 2011-2012 with rising stars accounting for almost 70% of crossover paper. We expect this relationship to revert back to predominantly fallen angels, and our list of crossover candidates has relatively few rising star names, and only one candidate with greater than \$3bn par outstanding. We define falling angels and rising stars using the Citi Indices, which are based on S&P and Moody's ratings. Credits with five-B ratings are included in Citi's Investment Grade Index.

Figure 4. Citi Index Migration (total par amt)



Source: Citi Research

Figure 5. Number of Crossover Issuers




Source: Citi Research

While fallen angels are a small portion of the IG market (S&P states that, on average, they account for only 1.98% of the total rated IG universe), the move from investment grade to high yield can have a meaningful impact on the overall market, depending on the amount of bonds outstanding. And while the move out of IG may not dent the high grade market, it could represent meaningful new net supply for high yield.

In the section below we discuss the most relevant candidates, and our trade recommendations. In the following tables we present the ratings and outlooks for the potential "Falling Angels" or "Rising Stars". Key themes driving the crossover migration include European concerns, shareholder pressure, and low borrowing costs enabling companies to lever up. Fallen angel candidates are mainly from sectors experiencing secular weakness (metals) or companies with struggling businesses. Although the spread differential between BBB and BB-rated companies has narrowed significantly, it seems that most companies are averse to high yield ratings and want to maintain their investment grade ratings.

In high yield, low natural gas prices have helped chemical companies while housing and autos have benefited from a cyclical turn and industry restructuring. A key factor determining whether high yield companies migrate to investment grade is management's long-term commitment to the ratings. While many high yield companies may have investment grade credit metrics, financial policies (i.e., shareholder friendly activities), leverage targets, and overall cash usage often influence rating agency decisions.

Figure 6. Falling Angel Spreads (OAS bp)



Source: Citi Research

Falling Angel Candidates

Alcoa (Baa3, Under review for downgrade / BBB-, Stable): On the back of weak Q3 2012 earnings due to continued pressure in the global aluminum market, Moody's placed Alcoa's Baa3 rating on review for downgrade in mid-December. The agency cited the weak results that have hampered credit metrics, including leverage that increased to about 6.0x. However, we expected a downgrade to HY post Q4 earnings that were okay, but metrics remained challenged and more in line with a HY credit profile.

We expect the credit to be downgraded if end markets continue to be weak, and if Alcoa is unable to improve its cost profile and leverage. However, we do not rule out the prospect of the agencies giving AA more time to reduce debt, allowing this American bellwether to remain investment grade.

Trading strategy: If the company were to be downgraded, we'd expect spreads to widen from here to levels in line with MTNA, which would call for about 50bp of backup. We suggest lightening up on paper as we believe a downgrade is likely, and for fundamental reasons as the end market outlook hasn't yet turned the corner.

Avon Products (Baa2, Stable / BBB-, Negative): Avon, the direct cosmetic seller, is a well recognized brand with strong global market share. However, as of late the company has had difficulty maintaining operating performance, and as a result, profitability has slipped and leverage has increased beyond a level typically tolerated for its current rating. S&P is expecting the company to use its adequate liquidity to reduce debt in 2013, allowing for a reduction in leverage. The company's issuance earlier this month and cash on hand will be used to repay debt, reducing leverage to around 3.0x, well within S&P's threshold for remaining IG. As such, we think Moody's and S&P will continue to assign investment grade ratings to Avon. However, we believe continued earnings pressure may eventually weigh on credit metrics and ratings, but the company now has a significant amount of leeway to improve its operations.

Trading strategy: AVP bonds are likely at fair value given its current earnings profile. We do not expect significant improvement to earnings, but with management demonstrating a commitment to debt reduction, we'd expect spreads to slowly drift tighter.

Transocean (Baa3, Negative / BBB-, Negative): Despite best efforts from Transocean's management team to reduce debt to a level more appropriate for an IG rating, pushes from shareholders to return capital may derail those best intentions. While the company's outlook is still dependent on lingering Macondo-related litigation, and higher than its peer group's leverage, any shareholder friendly activity beyond the company's current proposal would be viewed as credit negative.

The fate of RIG's rating is really in the hands of shareholders, and if they force either a dividend payment in excess of the proposed \$800mm, or that plans to reduce debt are put on hold, we believe a downgrade would occur. However, under current plans that call for a \$2.24 / share dividend and debt repayment, IG ratings would likely remain.


Trading strategy: It is becoming increasingly clear to us that shareholders wield increasing power, and given the already strained credit metrics, we are inclined to think spreads look a bit tight at current levels. If shareholders pass a higher dividend, we believe spreads would widen substantially.

Figure 7. Potential Falling Angel Candidates

Company	Industry	Moody's	S&P	Amt Out (\$mn)	Weighted Avg. OAS	Reasoning	Things to Watch	Ratios for a Downgrade*	Timing for Downgrade
Alcoa (AA)	Metals	Baa3 / UR	BBB- / Stable	6,927	Current: 295 12m range: 288-361	S&P seems to be giving AA a pass for 2013 on its leverage metrics outside the usual bounds, but they expect improvement in 2014.	S&P assumes AA will reduce debt and that aluminum prices will recover to \$0.95/lb in 2013 and \$1.00/lb in 2014. Look for changes to financial policy.	<ul style="list-style-type: none"> Aluminum prices fall below projections Prolonged debt / EBITDA >4.0x FFO / total debt needs to improve above 20% 	12 months
AngloGold Ashanti (AU)	Metals	Baa2 / Stable	BBB- / Negative	2,750	Current: 328 12m range: 323-406	High unit cash costs and substantial capex program that hamper cash generation ability. Concentrated exposure to South African gold mining.	Gold prices, and the South African government's stance on mining. Cash costs need to come down, but may be pressured by govt actions. Focus on scope of capex plans.	<ul style="list-style-type: none"> FFO / debt falls below 30-35% 	12 months
Avon Products (AVP)	Consumer	Baa2 / Stable	BBB- / Negative	1,725	Current: 224 12m range: 118-336	Pressure on the business from weakening operating results and increasing leverage. Market share is slipping.	Focus on operating performance, and leverage in particular. S&P is relying on debt reduction via FCF in 2013.	<ul style="list-style-type: none"> Sustained adjusted leverage above 3.5x (~3.7x currently) 	Remains IG
Cliffs Natural Resources (CLF)	Metals	Baa3 / Stable	BBB- / Stable	2,900	Current: 296 12m range: 238-435	Recent equity raise, dividend cut and planned debt reduction takes near term likelihood of a downgrade off the table.	Management has stated a commitment to IG, but need leverage to improve. Watch for potential shift in shareholder friendly tone.	<ul style="list-style-type: none"> Prolonged debt / EBITDA needs to be under 3.5x 	Remains IG
Genworth (GNW)	Insurance	Baa3 / Stable	BBB- / Negative	3,600	Current: 255 12m range: 255-591	Rating and outlook reflect low coverage metrics, choppy business performance and the drag from the mortgage insurer business. While prospective strategic actions should improve the company's outlook, lagging businesses remain a drag until the plan is executed.	Look for progress on the strategic plan and for a decrease in operating performance volatility. Financing costs continue to trend higher than peers.	<ul style="list-style-type: none"> 3-5x GAAP interest coverage Hold at least 2x holding company interest expense 	Remains IG
Harsco (HSC)	Industrial	Baa3 / UR	BBB- / Negative	700	Current: 206 12m range: 108-258	Key markets, including European construction and steel production, remain soft and cash generation is limited. Expectation is for recovery in 2013.	Profitability needs to improve, and cash generation may still be strained given heavy capex spending.	<ul style="list-style-type: none"> Downgrade risk if operating margins remain below 7% Looking for free OCF to exceed \$75mm 	12 months
Molson Coors Brewing (TAP)	Consumer	Baa2 / Stable	BBB- / Negative	1,900	Current: 124 12m range: 99-219	Concern around the company's aggressive financial policy, which financed a large acquisition with debt.	Management's commitment to credit quality, versus returning funds to shareholders or pursuing further debt-funded acquisitions.	<ul style="list-style-type: none"> By year end 2013: <ul style="list-style-type: none"> Leverage under 4.0x FFO / total debt ~20% Need to sustain adequate liquidity 	Remains IG
Transocean (RIG)	Energy	Baa3 / Negative	BBB- / Negative	8,900	Current: 232 12m range: 190-317	Recent pushes by shareholders to increase the dividend before delevering is a concern, as are remaining Macondo risks. The debt load is heavy, and capex plans are substantial.	Look for any ruling / charges related to Macondo, and if management caves to shareholder demands at the expense of bondholders.	<ul style="list-style-type: none"> By year end 2013: <ul style="list-style-type: none"> FFO / debt >25% Would likely be the result of revenues below \$9.5bn or EBITDA margin less than 39% 	6-9 months

Source: Citi Research, S&P, Moody's
*Based on S&P and Moody's requirements

Figure 8. Rising Star Spreads (OAS bp)



Source: Citi Research

Rising Star Candidates

Celanese Corp (Ba2, Positive / BB, Positive): Celanese is a chemical producer with a diverse product and geographical footprint and leading market technology. The company's new CEO has publicly stated that he wants to attain investment grade ratings and has made progress on this front, reducing secured debt down to 52% from 67% of total debt in the fourth quarter. We think the company will continue to move towards an unsecured capital structure. Citi's HY chemicals analyst, James Finnerty, believes that Celanese is a solid crossover candidate with positive event risk and is Overweight the credit ([Celanese Corp. \(CE\)](#)).

Trading strategy: Celanese trades 100bp behind the BBB Index and IG peers, with the CE '22s trading 122bp wide of Dow '22s. We think this relationship should compress as the company continues to move towards its investment grade target.

Delphi Automotive (Ba1, Stable / BB+, Positive): Delphi is positioned to benefit from secular trends in autos focused on fuel economy, safety and electronics. Although ratings agencies have expressed European exposure (45% of sales) as a key uncertainty for the company, Delphi has been able to produce strong results in a difficult macro environment. Despite share buybacks and dividend initiation, Delphi has ample liquidity and has been moving towards an unsecured capital structure. We think Delphi should be able to continue to execute its business strategy and has the potential to get upgraded in the near future. S&P raised its outlook on Delphi to Positive on February 11th, stating "there is a one-third probability that we could raise the ratings in the next year."

Trading strategy: Delphi currently trades 74bp wide of the BBB Index and should continue to tighten as the company delivers results. Delphi already has an investment grade rating at Fitch (BBB-), so an upgrade by one agency will move the company into most IG indices.

Sally Beauty Holdings (Ba3, Positive / BB+, Positive): Sally, the distributor of beauty products, has exhibited strong organic sales growth in a fairly stable, non-cyclical business line. The recent exit by private equity sponsors of their remaining stake is a positive for the credit as ratings agencies previously stated that private equity ownership was an impediment for an upgrade. Sally generates strong free cash flow and we believe any shareholder friendly actions should be funded with internal cash.

Trading strategy: Sally bonds are trading an average of 146bp wide of the BBB index, making it one of the most attractive candidates for spread tightening from a ratings upgrade.

TRW Automotive (Ba2, Stable / BB+, Positive): Although rated BBB- by Fitch, we don't think TRW will completely migrate to investment grade in the near future. The company continues to pursue shareholder friendly activities and announced a new \$1bn share repurchase program in 4Q 2012, which may be partially funded by its recently issued 4.5% notes. TRW's high exposure to Europe (43% of sales) will also likely prohibit achieving IG ratings as that market is expected to continue to deteriorate. Cit's HY auto analyst, Manish Somaiya, highlighted the bearish view on the European market in his piece, [European Auto Industry Trends](#).

Trading strategy: We would recommend selling TRW given that it already trades like a low BBB credit and we think it is unlikely to migrate to IG. Furthermore, spreads are slightly off their 12 month low and we believe investors are not well compensated for the risk of earnings deteriorating or further debt-funded shareholder friendly activities.

Figure 9. Potential Rising Star Candidates

Company	Industry	Moody's	S&P	Amt Out (\$mn)	Average OAS	Reasoning	Things to Watch	Ratios for an Upgrade*	Timing for Upgrade
Ashland (ASH)	Chemicals	Ba1, Stable	BB, Stable	2,450	Current: 249 12m range: 229 - 313	Management is focused on achieving IG ratings. Recent \$2.3bn bond issuance and term loan pay down move the company towards unsecured capital structure.	S&P expects ASH's credit profile will continue to improve through earnings growth and debt reduction via FCF. Management has a leverage target of 2.0x	<ul style="list-style-type: none"> EBITDA margins >12% Retained Cash Flow/Debt at least 20% FCF/Debt at least 10% FFO to debt 20-25% 	12-24 months
Celanese (CE)	Chemicals	Ba2, Positive	BB, Positive	1,500	Current: 281 12m range: 227 - 443	Diverse geographic and product exposure with solid operating performance. Management has stated IG ratings as a goal.	Continue refinancing of secured debt with unsecured. Agencies are looking for specific financial metric guidance from management. Acquisitions with cash that will increase EBITDA and cash flow would be positive for ratings.	<ul style="list-style-type: none"> Total Debt/EBITDA below 3.3x Retained Cash Flow/Debt near 20% FFO to Debt 25-30% 	18 months
CIT Group (CIT)	Financials	Ba3, Stable	BB-, Positive	11,750	Current: 221 12m range: 221 - 474	While a much longer term story, CIT could be upgraded over time. The company has improved earnings, lowered borrowing costs and repaid debt.	CIT needs to demonstrate Q4 results as a run-rate.	<ul style="list-style-type: none"> Core pretax ROA for more than 1.25% 	24 months
CNH Group (CNH)	Industrials	Ba2, Stable	BB+, Stable	3,002	Current: 281 12m range: 267 - 444	Leader in farm equipment market with improving competitive position and credit metrics.	Further upgrade is dependent on improvement at Fiat Industrial. Closing the \$2.3bn liquidity shortfall. Clarity on pro-forma capital structure of the overall company.	<ul style="list-style-type: none"> EBIT/Interest 4.0x Debt/EBITDA < 3.0x 	Remains HY
Continental Resources (CLR)	Energy	Ba1, Stable	BB+, Positive	2,900	Current: 234 12m range: 221 - 408	Potential for growth in reserves and production in the attractive Bakken Shale region.	Continued increase in production and reserves with a conservative capital structure. Moody's is looking for production diversification and takeaway infrastructure in the Bakken.	<ul style="list-style-type: none"> Maintain leverage of 1.5x 	12 months
Delphi (DLPH)	Autos	Ba1, Stable	BB+, Positive	1,800	Current: 256 12m range: 245 - 376	Positioned to benefit from secular trends in autos focused on fuel economy, safety and electronics.	Continued performance amid weak European markets. Ability to generate FCF to sustain shareholder friendly activities. Repayment of secured debt with unsecured debt.	<ul style="list-style-type: none"> Adj margins > 13% FCF range of 10-25% throughout a cycle Debt/total capital < 45% Leverage 2.0x or less 	12 months
DR Horton (DHI)	Homebuilder	Ba2, Positive	BB-, Positive	2,239	Current: 241 12m range: 214 - 373	Leading cash flow generation and low leverage in the industry.	Net income growth as market recovers. Maintenance of liquidity position amid land spend.	<ul style="list-style-type: none"> Maintaining debt leverage close to 40% Mid-teen sales growth EBITDA margins in the low 9% area 	24 months
Sally Beauty (SBH)	Consumer	Ba3, Positive	BB+, Positive	1,600	Current: 328 12m range: 291 - 423	Strong organic sales growth in a fairly stable, non-cyclical business line, private equity ownership exit	Continued improvement in operating and credit metrics. Balance of debt reduction and shareholder friendly activities.	<ul style="list-style-type: none"> Debt/EBITDA below 4.0x (lease-adjusted basis) EBITDA/interest >3.25x 	12 months
Toll Brothers (TOL)	Homebuilder	Ba1, Stable	BB+, Stable	1,638	Current: 225 12m range: 210 - 352	Improving operating metrics, conservative capital structure, and growing tower and luxury businesses.	Overall housing market recovery. Negative cash flow for land investments. Continued earnings improvement.	<ul style="list-style-type: none"> Debt/EBITDA 2.0x-3.0x Interest coverage in the mid single-digits Gross margins >23% 	18 months
TRW Automotive (TRW)	Autos	Ba2, Stable	BB+, Positive	970	Current: 234 12m range: 203-363	Currently meets credit metrics for upgrade, but exposure to European markets, uncertainty around the anti-trust investigation, and the company's \$1bn share buyback program may impair liquidity.	Continued earnings performance despite weak European auto market. European anti-trust investigation settlement. Impact of shareholder friendly activity on liquidity.	<ul style="list-style-type: none"> EBITDA margins of 10-11% FFO/Debt of 40% or better Debt/Capital < 45% 	Remains HY

Source: Citi Research, S&P, Moody's

*Based on S&P and Moody's Requirements

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Inc

Erin Lyons; Julie Pearson; Lili Yang

OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Research research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to Citi Research research reports.

Important disclosure regarding the relationship between the companies that are the subject of this Citi Research research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

This Citi Research research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of Citi Research. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comisión Nacional Bancaria y de Valores. Reforma 398, Col. Juárez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ("FAA") through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any

information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Büyükdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual

preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2013 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
